Track topics on Twitter Track topics that are important to you
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
Appropriate treatment of anxiety is of paramount importance in the primary care setting. Family practice providers are in a position to best understand each patient's background, resources and challen...
Genentech’s phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) show positive results
An estimated 100,000 Canadians live with multiple sclerosis; there is currently no cure for the disease. Modern scientific understanding has considered multiple sclerosis (MS) to be a disease contr...
Novartis is acquiring all the remaining rights to GlaxoSmithKline’s (GSK) multiple sclerosis (MS) drug, Ofatumumab. A fully human monoclonal antibody which targets the CD20 molecule, Ofatumumab ...
Researchers have made another important step in the progress towards being able to block the development of multiple sclerosis (MS) and other autoimmune diseases.
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 1.5%, according to ...
In a paper published in Nature Reviews Neurology, researchers at Monash University have revealed that eye movement measures can help identify the presence and progression of Multiple Sclerosis (MS).
Roche today announced data from three positive, pivotal Phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
To date, there are no available factors to predict the outcome after multiple sclerosis relapse.
Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database.
Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS).
Cognitive deficits are common in multiple sclerosis. Most previous studies investigating the imaging substrate of cognitive deficits in multiple sclerosis included patients with relatively short disea...
Recent studies on date of birth of multiple sclerosis (MS) patients showed an association between month of birth and the risk of developing MS. This association has not been investigated in an African...
In search of the missing heritability in multiple sclerosis (MS), additional approaches adding to the genetic discoveries of large genome-wide association studies are warranted.